



QFW

PATENT  
DOCKET NO. SPV-046.02

In re Application of:

Cuny, G., et al.

Application No: 10/786,612

Filed: February 25, 2004

For: Thiazole and Other Heterocyclic  
Ligands for Mammalian Dopamine,  
Muscarinic and Serotonin  
Receptors and Transporters, and  
Methods and Use Thereof

Art Unit: 1626

Examiner: Not Yet Assigned

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 28, 2004

  
John Barretto

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Under 35 U.S.C. §120, this application has the benefit of the filing date of U.S. Patent Application 10/123,089, filed April 12, 2002. With the exception of references AI and AV, copies of all references listed in the Form PTO-1449 were submitted to the Office in the parent application; therefore, copies of them are not required with this Statement. Because the instant application was filed after June 30, 2003, a copy of reference AI (US Patent 6,107,313) is not provided. A copy of reference AV is supplied.

**REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that **[check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]**:

- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Respectfully submitted,



Dana M. Gordon, Ph.D.  
Attorney/Agent for Applicant(s)  
Foley Hoag LLP  
155 Seaport Boulevard  
Boston, Massachusetts 02210-2600

Date: May 28, 2004  
Reg. No. 44,719

Tel. No. (617) 832-1000  
Fax No. (617) 832-7000

Form PTO-1449

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**  
*(Use several sheets if necessary)*

Docket Number (Optional)

SPV-046.02

Application Number

10/786,612

Applicant  
Cuny, G., et al.Filing Date  
2/25/04Group Art Unit  
1626

JUN 01 2004

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	US 6,057,340	05/02/00	Kelly et al.	514	326	
AB	US 5,780,468	07/14/98	Bernat et al.	514	236.8	
AC	US 5,674,890	10/07/97	Christophe et al.	514	438	
AD	US 5,464,847	11/07/95	Courtemanche et al.	514	342	
AE	US 5,462,939	10/31/95	Dolle et al.	514	231.5	
AF	US 5,232,921	08/03/93	Biziere et al.	514	231.5	
AG	US 5,081,199	01/14/92	Biogegrain et al.	514	231.5	
AH	US 5,017,579	05/21/91	Gubin et al.	514	299	
AI	US 6,107,313 A	08/22/00	William et al.	514	340	

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
AJ	WO 99/62890	12/09/99	PCT				X
AK	WO 99/32464	07/01/99	PCT				X
AL	WO 99/11637	03/11/99	PCT				X
AM	WO 98/41528	09/24/98	PCT				X
AN	WO 98/25904	06/18/98	PCT				X
AO	WO 95/07694	03/23/95	PCT				X
AP	WO 92/03134	03/05/92	PCT				X
AQ	WO 91/09857	07/11/91	PCT				X
AR	EP 0 702015 A1	03/20/96	European Patent Application				X
AS	EP 0659747 B1	04/01/98	European Patent Specification				X
AT	EP 0 636 624 A1	02/01/95	European Patent Application				X
AU	EP 0 283 390 A1	09/21/88	European Patent Application				X

**OTHER DOCUMENTS***(Including Author, Title, Date, Pertinent Pages Etc.)*

AV	Williams, et al.; "A Solution-Phase Combinatorial Synthesis of Selective Dopamine D4 Ligands," Combinatorial Chemistry and High Throughput Screening, 2000, Vol. 3, No. 1, pp. 43-50.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.